David Westenberg
Stock Analyst at Piper Sandler
(4.45)
# 376
Out of 4,983 analysts
174
Total ratings
58%
Success rate
17.69%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WGS GeneDx Holdings | Maintains: Overweight | $120 → $140 | $121.37 | +15.35% | 3 | Sep 11, 2025 | |
| TXG 10x Genomics | Initiates: Neutral | $15 | $13.13 | +14.24% | 2 | Sep 11, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.25 → $1.5 | $1.23 | +21.95% | 9 | Aug 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $210 → $215 | $147.46 | +45.80% | 15 | Aug 11, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $510 → $700 | $645.65 | +8.42% | 11 | Aug 11, 2025 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $12 → $18 | $18.63 | -3.38% | 10 | Aug 11, 2025 | |
| NTRA Natera | Maintains: Overweight | $210 → $220 | $175.01 | +25.71% | 16 | Aug 11, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $60 | $52.94 | +13.34% | 11 | Aug 11, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $13 → $15 | $12.91 | +16.19% | 14 | Aug 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $11 | $7.99 | +37.67% | 10 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $21 | $21.94 | -4.28% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $70 | $87.04 | -19.58% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $185 | $101.48 | +82.30% | 16 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $260 → $280 | $274.09 | +2.16% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $55.40 | +8.30% | 9 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $180.16 | +11.01% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $5.27 | -5.12% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.91 | +104.60% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $29.53 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $44.47 | - | 1 | Nov 21, 2017 |
GeneDx Holdings
Sep 11, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $121.37
Upside: +15.35%
10x Genomics
Sep 11, 2025
Initiates: Neutral
Price Target: $15
Current: $13.13
Upside: +14.24%
Pacific Biosciences of California
Aug 11, 2025
Maintains: Neutral
Price Target: $1.25 → $1.5
Current: $1.23
Upside: +21.95%
Zoetis
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $147.46
Upside: +45.80%
IDEXX Laboratories
Aug 11, 2025
Maintains: Neutral
Price Target: $510 → $700
Current: $645.65
Upside: +8.42%
Elanco Animal Health
Aug 11, 2025
Maintains: Neutral
Price Target: $12 → $18
Current: $18.63
Upside: -3.38%
Natera
Aug 11, 2025
Maintains: Overweight
Price Target: $210 → $220
Current: $175.01
Upside: +25.71%
Exact Sciences
Aug 11, 2025
Maintains: Overweight
Price Target: $70 → $60
Current: $52.94
Upside: +13.34%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $13 → $15
Current: $12.91
Upside: +16.19%
NeoGenomics
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $7.99
Upside: +37.67%
Aug 4, 2025
Maintains: Neutral
Price Target: $23 → $21
Current: $21.94
Upside: -4.28%
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $87.04
Upside: -19.58%
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $101.48
Upside: +82.30%
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $274.09
Upside: +2.16%
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $55.40
Upside: +8.30%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $180.16
Upside: +11.01%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $5.27
Upside: -5.12%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.91
Upside: +104.60%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $29.53
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $44.47
Upside: -